Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072683 · ClinicalTrials.gov registry record · Phase 3
"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00072683 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 240 participants.
The verdict
NCT00072683, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study's purpose is to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal, and to characterize and quantify the potential clinical benefits of this treatment.
Interventions
- DRUG tolvaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2003-04 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072683
The ClinicalTrials.gov registry entry for NCT00072683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tolvaptan is the first listed.
NCT00072683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072683 about?
NCT00072683 is a clinical study titled ""SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia". This study's purpose is to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal, and to characterize and quantify the potential clinical benefits of this treatment.
What is the current status of trial NCT00072683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2003-04. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00072683?
The interventions under investigation include: tolvaptan (DRUG).
Who is sponsoring clinical trial NCT00072683?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.